Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cash-Strong Vical Narrows Focus To Two Lead Programs

This article was originally published in The Pink Sheet Daily

Executive Summary

Wary of current financial environment, biotech is bullish on early pipeline projects but will await partners to advance them.

You may also be interested in...



Vical Joins Forces With Astellas On CMV Vaccine

Vaccine-focused biotech Vical Inc. announced July 14 that it has inked a global licensing agreement with Japan's Astellas Pharma Inc. to develop and commercialize the biotech's cytomegalovirus (CMV) vaccine, TransVax

Vical Joins Forces With Astellas On CMV Vaccine

Astellas will take over the development of TransVax and pay Vical $103 million plus royalties.

Vical Joins Forces With Astellas On CMV Vaccine

Astellas will take over the development of TransVax and pay Vical $103 million plus royalties.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel